What's Happening?
Eli Lilly has announced promising results for its drug Jaypirca in treating chronic lymphocytic leukemia (CLL). The BRUIN CLL-322 trial, presented at the EHA congress, demonstrated that adding Jaypirca, a non-covalent BTK inhibitor, to the standard second-line
treatment regimen of Venclexta and rituximab significantly reduced the risk of disease progression or death by 45%. After two years, 86.9% of patients on the Jaypirca regimen were alive without disease progression, compared to 71.8% on the standard regimen alone. The trial included patients previously treated with older BTK inhibitors, showing resistance to them. The addition of Jaypirca was noted to control cancer longer without adding significant toxicity, suggesting it could benefit a wide range of patients, including those with other medical conditions.
Why It's Important?
The results from the BRUIN CLL-322 trial could potentially change the standard of care for patients with relapsed or refractory CLL. The significant improvement in progression-free survival with the Jaypirca regimen highlights its potential as a more effective treatment option. This could lead to an expanded market for Jaypirca, which already saw $506 million in global sales last year. Analysts predict that if the triplet regimen is approved, it could generate revenues of up to $2.5 billion by 2030. The findings also support the drug's use in a broader patient population, potentially improving outcomes for those who have exhausted other treatment options.
What's Next?
Eli Lilly plans to submit the new trial results to global regulatory authorities to seek an extension of Jaypirca's label. This could increase the drug's market potential significantly. Additionally, Lilly is exploring Jaypirca's efficacy in the first-line setting, with recent data showing it outperformed chemoimmunotherapy in untreated CLL patients. These developments could further solidify Jaypirca's role in CLL treatment and expand its use in clinical practice.
